NIAID SBIR-Technology Transfer Direct Phase II (R44)


The goal of this Funding Opportunity Announcement (FOA) is to move commercially-viable vaccines and products for treatment and prevention of diseases relevant to NIAID's mission from NIAID intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) for projects that incorporate the appropriate research expertise (company, NIAID Intramural or external collaborators/consortiums) to further develop and commercialize such inventions. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type research and development, to expand research and development opportunities for applicant SBCs, and to enhance the pace of technology development and commercialization.

General information about this opportunity
Last Known Status
Program Number
Federal Agency/Office
Agency: Department of Health and Human Services
Office: National Institutes of Health
Type(s) of Assistance Offered
Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
What is the process for applying and being award this assistance?
Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements.
Who do I contact about this opportunity?
Headquarters Office
NIH OER Webmaster
Website Address
E-mail Address
Financial Information


Related Federal Grants

Federal Grants Resources